Novavax, Inc. (NASDAQ:NVAX) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its stake in Novavax, Inc. (NASDAQ:NVAX - Free Report) by 3.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,365,414 shares of the biopharmaceutical company's stock after acquiring an additional 39,906 shares during the period. Charles Schwab Investment Management Inc. owned 0.85% of Novavax worth $10,978,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Shah Capital Management grew its stake in Novavax by 13.6% during the 4th quarter. Shah Capital Management now owns 11,148,846 shares of the biopharmaceutical company's stock worth $89,637,000 after buying an additional 1,333,305 shares during the last quarter. State Street Corp grew its position in shares of Novavax by 26.7% during the third quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company's stock worth $97,099,000 after acquiring an additional 1,621,772 shares during the last quarter. Geode Capital Management LLC raised its position in Novavax by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 3,502,489 shares of the biopharmaceutical company's stock valued at $44,245,000 after purchasing an additional 304,159 shares during the last quarter. Bank of Montreal Can boosted its stake in Novavax by 26.7% during the 3rd quarter. Bank of Montreal Can now owns 2,454,325 shares of the biopharmaceutical company's stock worth $32,643,000 after purchasing an additional 517,727 shares during the period. Finally, Two Sigma Advisers LP grew its position in Novavax by 48.9% during the 3rd quarter. Two Sigma Advisers LP now owns 1,999,400 shares of the biopharmaceutical company's stock worth $25,252,000 after purchasing an additional 656,900 shares during the last quarter. Institutional investors and hedge funds own 53.04% of the company's stock.

Remove Ads

Analyst Ratings Changes

A number of equities analysts recently issued reports on NVAX shares. BTIG Research started coverage on Novavax in a report on Friday, February 28th. They set a "buy" rating and a $19.00 price target on the stock. HC Wainwright restated a "buy" rating and set a $19.00 price target on shares of Novavax in a research note on Tuesday, December 10th. Finally, TD Cowen raised shares of Novavax to a "hold" rating in a research note on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $18.00.

Insider Buying and Selling at Novavax

In related news, Director James F. Young sold 5,400 shares of the business's stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $8.00, for a total value of $43,200.00. Following the sale, the director now directly owns 51,760 shares in the company, valued at $414,080. The trade was a 9.45 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.00% of the stock is owned by corporate insiders.

Novavax Price Performance

Shares of NASDAQ NVAX traded down $0.13 during trading on Tuesday, hitting $7.56. 2,259,677 shares of the company were exchanged, compared to its average volume of 7,999,577. The firm's fifty day moving average price is $8.23 and its 200 day moving average price is $9.46. The company has a market cap of $1.22 billion, a price-to-earnings ratio of -3.35, a PEG ratio of 2.85 and a beta of 2.92. Novavax, Inc. has a 1 year low of $3.81 and a 1 year high of $23.86.

Novavax (NASDAQ:NVAX - Get Free Report) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.75) by $0.24. The company had revenue of $88.31 million during the quarter, compared to analysts' expectations of $85.48 million. During the same period last year, the business posted ($1.44) earnings per share. On average, research analysts forecast that Novavax, Inc. will post -1.46 earnings per share for the current year.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.